China's CanSino Biologics in talks with other nations for Phase III COVID-19 vaccine trial

Chinese vaccine developer CanSi Biologics is reportedly in talks with Russia, Brazil, Chile, and Saudi Arabia for Phase III trial of its COVID-19 vaccine candidate. Qiu Dongxu, executive director and co-founder of CanSi, told an anti-viral drug development conference that company is contacting those countries but thing has been finalised yet.

China has successfully flattened coronavirus infection curve and low number of active cases has me it difficult for companies to conduct large-scale vaccine trials. Qiu said that firm plans to recruit 40,000 participants for Phase III trial which is likely to start “pretty soon”, without giving a specific date for kick-off.

vaccine candidate, 5-nCoV, has been jointly developed by CanSi and Beijing Institute of Biotechlogy in Acemy of Military Medical Sciences. According to media reports, both initial phases of clinical testing of candidate vaccine has displayed its potential of preventing COVID-19.

5-nCov was first COVID-19 vaccine candidate in China to go ahe with human testing in March but has been lagging in trial progress since two or experimental vaccines developed by Sivac Biotech and a unit of China National Pharmaceutical Group (Sipharm) have alrey been approved for Phase III trials.

Re: CanSi's Vaccine For COVID-19 Gets d For Military Use In China

Or vaccine candidates

Sivac Biotech, first company in world to market H1N1 vaccine, received approval to conduct phase I and phase II study on its inactivated vaccine candidate against COVID-19 in April. pharma company h commenced phase I trial and ministered drug on 144 healthy ults d 18-59 years.

Sivac CEO Weidong Yin said in a statement that vaccine candidate induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and n-human primates, specifically rhesus macaque. results showed that vaccine candidate offered safe and complete protection in rhesus macaques against SARS- CoV-2 strains, he ded.

“As we begin our phase I trials, we will also accelerate progress of our research in order to support worldwide fight against COVID-19. Sivac remains committed to developing vaccines for global use,” said Weidong.

Re: Russian Scientists Successfully Complete World’s First COVID-19 Vaccine Trial

(Representational Im: pixabay)